Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

Objectives: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid arthritis (RA). Methods: During a 12 week, double blind, placebo controlled study, 284 patients were...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: van de Putte, L B A, Rau, R, Breedveld, F, Kalden, J, Malaise, M, van Riel, P L C M, Schattenkirchner, M, Emery, P, Burmester, G, Zeidler, H, Moutsopoulos, H, Beck, K, Kupper, H
Formato: Artigo
Lenguaje:Inglês
Publicado: 2003
Materias:
Extended Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1754401/
https://ncbi.nlm.nih.gov/pubmed/14644854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2003.009563
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares